Glioblastoma: the current state of the problem
https://doi.org/10.21886/2219-8075-2019-10-4-28-35
Abstract
A brief literature review of modern scientifi c data on the biology of the most malignant neuroepithelial tumors — glioblastomas of the central nervous system is presented. Th e article discusses the issues of epidemiology, classifi cation, molecular genetic and radiological diagnostics, as well as the complex treatment of this type of tumor in adult (> 20 years old) patients. Genetic and biochemical factors of glioblastoma development are described in detail, the main prognostic criteria for the eff ectiveness of chemotherapy are presented. Th e article concludes with an overview of the main trends in the development of experimental treatment methods.
About the Author
Y. G. Yakovlenko
Rostov State Medical University;
Rostov Regional Advisory and Diagnostic Centre
Russian Federation
Russian Federation
Cand. Sci. (Med.), Neurosurgeon in Department of Neurosurgery, Clinic; Assistant of the Department of Neurology and Neurosurgery, Faculty of General Medicine;
neurosurgeon,
Rostov-on-Don
References
1. Zolotova SV, Khokhlova EV, Belyashova AS, Nikolaeva AA, Starovoytov DV, et al. Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis. Zh Vopr Neirokhir Im N N Burdenko . 2019;83(2):17-26. (In Russ.) doi: 10.17116/neiro20198302117
2. Goryaynov SA, Gol’dberg MF, Golanov AV, Zolotova SV, Shishkina LV, et al. The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H). Zh Vopr Neirokhir Im N N Burdenko. 2017;81(3):5-16. (in Russ.) doi: 10.17116/neiro20178135-16
3. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-50. doi: 10.1001/jama.2013.280319.
4. Harbaugh R, Shaff rey CI, Couldwell WT, Berger MS eds. Neurosurgery knowledge update: a comprehensive review 1st Edition. New York: Thieme; 2015.
5. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosedin the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131
6. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, et al. Th e epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7), 896–913. doi: 10.1093/neuonc/nou087
7. Sundar SJ, Hsieh JK, ManJila S, Lathia JD, Sloan A. Th e role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6. doi: 10.3171/2014.9.FOCUS14494
8. Kobyakov GL, Absalyamova OV, Poddubskiy AA, Lodygina KS, Kobyakova EA. Th e 2016 WHO classifi cation of primary tumors of the central nervous system: a clinician’s opinion. Zh Vopr Neirokhir Im N N Burdenko. 2018;82(3):88-96. (In Russ.) doi: 10.17116/neiro201882388
9. Banan R, Hartmann C. Th e new WHO 2016 classification of brain tumors—what neurosurgeons need to know. Acta Neurochir 2017;159:403-418. doi: 10.1007/s00701-016-3062-3
10. Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurg Focus. 2014;37(6):E13. doi: 10.3171/2014.9.FOCUS14505.
11. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103(2):143-53. doi: 10.1093/jnci/djq497/
12. Margison GP, Kleihues P. Chemical carcinogenesis in the nervous system. Preferential accumulation of O6- methylguanine in rat-brain deoxyribonucleic acid during repetitive administration of N-methyl- N-nitrosourea. Biochem J. 1975;148:521–525. doi: 10.1042%2Fbj1480521
13. Goth R, Rajewsky MF. Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specifi c carcinogenesis by ethylnitrosourea. Proc Natl Acad Sci U S A. 1974;71:639–643.
14. Greenberg MS. Handbook of neurosurgery. Eighth Edition. New York: Thieme; 2016.
15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773. doi: 10.1056/NEJMoa0808710.
16. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–2710. doi: 10.1101/gad.1596707
17. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764–772. doi: 10.1158/1078-0432.CCR-12-3002
18. Bello MJ, Alonso ME, Aminoso C, Anselmo NP, Arjona D, et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res. 2004;554:23–32. doi: 10.1016/j.mrfmmm.2004.02.011
19. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter-methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C–>A:T mutations of theTP53tumor suppressor gene. Carcinogenesis. 2001;22:1715–1719. doi: 10.1093/carcin/22.10.1715
20. Parsons DW, Jones S, Zhang X., Lin JC, Leary RJ, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. doi: 10.1126/science.1164382
21. Rumboldt Z, Castillo M, HuangB, Rossi A. Brain imaging with MRI and CT. An image pattern approach. Cambridge university press; 2012.
22. Sartor K., Haehnel S., Kress B. Direct diagnosis in radiology: Brain imaging. Stuttgart: Thieme; 2008.
23. Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6(4):40. doi: 10.21037/cco.2017.06.28
24. Lee SK. Diff usion tensor and perfusion imaging of brain tumors in high-fi eld MR imaging. Neuroimaging Clin N Am. 2012;22:123-34, ix. doi: 10.1016/j.nic.2012.02.001.
25. Absalyamova OV, Kobyakov Gl, Ryzhova MV, Poddubskiy AA, Inozemtseva MV, Lodygina KS. Outcomes of application of modern fi rst-line chemotherapy regimens in complex treatment of glioblastoma patients. Zh Vopr Neirokhir Im N N Burdenko. 2019;83(2):17-26. doi: 10.17116/neiro20168065-14
26. Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, et al. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. – 2016. – V.2. – P.1460-9. doi: 10.1001/ jamaoncol.2016.1373
27. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401. doi: 10.1016/S1470-2045(06)70665-9
28. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987- 996. doi: 10.1056/NEJMoa043330
29. Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol. 2015;49(1):80–85. doi: 10.2478/raon-2014-0021
30. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology.2007;25(30):4722-4729. doi: 10.1200/JCO.2007.12.2440
31. Linhares P, Carvalho B, Figueiredo R, Reis R, Vaz R. Early pseudoprogression following chemoradiotherapy in glioblastoma patients: Th e Value of RANO Evaluation. Journal of Oncology. 2013;2013:1-9. doi: 10.1155/2013/690585
32. Puzzilli F, Ruggeri A, Mastronardi L, Di Stefano D, Lunardi P. Long-Term Survival in Cerebral Glioblastoma. Case Report and Critical Review of the Literature. Tumori Journal. 1998;84(1):69-74. doi: 10.1177%2F030089169808400115
33. Th omas AA, Ernstoff MS, Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J. 2012;18(1):59–68. doi: 10.1097/PPO.0b013e3182431a73
34. Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor effi cacy in human glioblastoma models. Neoplasia. 2013;15(6):591–599. doi: 10.1593%2Fneo.13158
Review
For citations:
Yakovlenko Y.G. Glioblastoma: the current state of the problem. Medical Herald of the South of Russia. 2019;10(4):28-35. (In Russ.) https://doi.org/10.21886/2219-8075-2019-10-4-28-35
Views:
19580
Email this article 